These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 24930319)
21. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone]. Kern KU; Krings D; Waldmann-Rex S MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028 [TBL] [Abstract][Full Text] [Related]
22. Economic burden and dosing trends of buprenorphine buccal film and transdermal patch in chronic low back pain. Zah V; Stanicic F; Vukicevic D; Grbic D Pain Manag; 2024; 14(4):195-207. PubMed ID: 38939964 [TBL] [Abstract][Full Text] [Related]
23. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884 [TBL] [Abstract][Full Text] [Related]
25. Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine. Hirst A; Knight C; Hirst M; Dunlop W; Akehurst R Eur J Health Econ; 2016 Mar; 17(2):217-27. PubMed ID: 25861916 [TBL] [Abstract][Full Text] [Related]
26. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study. Barutell C; Camba A; González-Escalada JR; Rodríguez M; Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364 [TBL] [Abstract][Full Text] [Related]
27. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain]. Tschirner M; Ritzdorf I; Brünjes R MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217 [TBL] [Abstract][Full Text] [Related]
28. Treatment characteristics of chronic low back pain patients treated with buprenorphine buccal film or transdermal patch. Stanicic F; Grbic D; Vukicevic D; Zah V Pain Manag; 2024 Jan; 14(1):35-48. PubMed ID: 38235537 [TBL] [Abstract][Full Text] [Related]
29. [Treatment of chronic osteoarthritis pain: effectivity and safety of a 7 day matrix patch with a low dose buprenorphine]. Schutter U; Ritzdorf I; Heckes B MMW Fortschr Med; 2008 Jun; 150 Suppl 2():96-103. PubMed ID: 18712130 [TBL] [Abstract][Full Text] [Related]
30. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Wolff RF; Aune D; Truyers C; Hernandez AV; Misso K; Riemsma R; Kleijnen J Curr Med Res Opin; 2012 May; 28(5):833-45. PubMed ID: 22443154 [TBL] [Abstract][Full Text] [Related]
31. A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression. Yarlas A; Miller K; Wen W; Lynch SY; Munera C; Dain B; Pergolizzi JV; Raffa R; Ripa SR Pain Pract; 2016 Apr; 16(4):473-85. PubMed ID: 25865734 [TBL] [Abstract][Full Text] [Related]
32. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Sorge J; Sittl R Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693 [TBL] [Abstract][Full Text] [Related]
33. Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. Miller K; Yarlas A; Wen W; Dain B; Lynch SY; Brennan MJ; Ripa SR Expert Opin Pharmacother; 2013 Feb; 14(3):269-77. PubMed ID: 23374027 [TBL] [Abstract][Full Text] [Related]
34. Transdermal buprenorphine in the treatment of chronic pain. Sittl R Expert Rev Neurother; 2005 May; 5(3):315-23. PubMed ID: 15938664 [TBL] [Abstract][Full Text] [Related]
35. A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids. Breivik H; Ljosaa TM; Stengaard-Pedersen K; Persson J; Aro H; Villumsen J; Tvinnemose D Scand J Pain; 2010 Jul; 1(3):122-141. PubMed ID: 29913983 [TBL] [Abstract][Full Text] [Related]
36. [Clinical practice data regarding tapentadol prolonged release treatment for severe chronic pain - improvement of analgesia, functional competence and quality of life in particular under tapentadol monotherapy]. Lange T; Krings D; Waldmann-Rex S MMW Fortschr Med; 2015 Apr; 157(157 Suppl 4):12-21. PubMed ID: 26013114 [TBL] [Abstract][Full Text] [Related]
37. US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system. Pergolizzi JV; Ben-Joseph R; Chang CL; Hess G Curr Med Res Opin; 2014 Aug; 30(8):1579-87. PubMed ID: 24689806 [TBL] [Abstract][Full Text] [Related]
38. Assessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational Study. Serpell M; Tripathi S; Scherzinger S; Rojas-Farreras S; Oksche A; Wilson M Patient; 2016 Feb; 9(1):35-46. PubMed ID: 26547914 [TBL] [Abstract][Full Text] [Related]
39. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Likar R; Vadlau EM; Breschan C; Kager I; Korak-Leiter M; Ziervogel G Clin J Pain; 2008; 24(6):536-43. PubMed ID: 18574363 [TBL] [Abstract][Full Text] [Related]
40. Endocrine and behavioural effects of transdermal buprenorphine in pain-suffering women of different reproductive ages. Aurilio C; Ceccarelli I; Pota V; Sansone P; Massafra C; Barbarisi M; Pace MC; Passavanti MB; Bravi F; Aloisi AM Endocr J; 2011; 58(12):1071-8. PubMed ID: 21937837 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]